ClinicalTrials.gg
TerminatedNCT03598036AURONA™Updated Sep 16, 2021Results posted

Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis

A Phase 2 interventional study of Voclosporin in Focal Segmental Glomerulosclerosis, sponsored by Aurinia Pharmaceuticals Inc.. Terminated at 23 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-09-16.

Sponsored by Aurinia Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Low recruitment rate

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States — 18 open to participants now, 21 under way, 2 of them phase 3. Glomerulosclerosis, Focal Segmental · United States.

Enrollment
50th of 56
5 · median 30
Started
2018
with 4 others
Phase 2
29 of 69
4 open now
Registered
36th of 69
by date

Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, this one is the 50th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2018, is one of 29 in phase 2, and was the 36th registered.

Glomerulosclerosis, Focal Segmental

106 studies on the registry are indexed under Glomerulosclerosis, Focal Segmental; 34 are open to participants now.

Browse Glomerulosclerosis, Focal Segmental studies →

Open to participants now

18 of the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Glomerulosclerosis, Focal Segmental studies recruiting now, 11 (35%) set no upper age limit and 13 (42%) stop at 75 or younger; 23 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, or all of them as a file.
02

Study summary

Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects with Focal Segmental Glomerulosclerosis

Read the detailed description

The aim of the current study to assess the efficacy of voclosporin in achieving complete or partial remission of proteinuria after 24 weeks of therapy in subjects with focal segmental glomerulosclerosis (FSGS). As well as to assess the safety and tolerability of voclosporin over 24 weeks in subjects with FSGS.

03

Conditions studied

  • Focal Segmental Glomerulosclerosis

Keywords

  • calcineurin inhibitors
  • Focal Segmental Glomerulosclerosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Primary FSGS diagnosed by renal .
  2. Urine protein creatinine ratio (UPCR) ≥2.0 mg/mg, serum albumin ≤3.2 g/dL and can be treatment-naïve, or receiving treatment with .
  3. Stable proteinuria, renal function, and BP.

Exclusion criteria

Exclusion Criteria:

  1. Clinical or histologic evidence of secondary FSGS.
  2. Histologic evidence of collapsing variant FSGS.
  3. as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation of ≤30 mL/minute/1.73 m2 at initial screening assessment or ≤45 mL/minute/1.73 m2 at last qualifying assessment.
  4. Currently requiring renal dialysis (hemodialysis or peritoneal dialysis) or expected to require dialysis during the study period.
  5. Current or medical history of:

    • Congenital or acquired immunodeficiency.
    • In the opinion of the Investigator, drug or alcohol abuse within 2 years prior to screening.
    • within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision.
    • Current or past lymphoproliferative disease or previous total lymphoid irradiation.
    • Severe viral infection within 3 months of screening, or known infection. Severe viral infection is defined as active disease requiring antiviral therapy.
    • Active tuberculosis (TB) or known history of TB/evidence of old TB if not taking prophylaxis with isoniazid.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Voclosporin

    Cohort 1: Maximum dose of 3 capsules (7.9mg) BID Cohort 2 Dosing to be decided based on the safety from the first 5 or 6 subjects in Cohort 1.

    Drug: Voclosporin

Interventions

  • Voclosporin softgel capsules. Up to 10 subjects will be enrolled into Cohort 1 and take up to 3 capsules twice daily (BID). The dose of voclosporin for Cohort 2 (at least 10 subjects) will be determined by analysis of efficacy and safety data at Week 12 from the first 5 or 6 subjects in Cohort 1.

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects With Remission of Proteinuria

    Complete remission OR Partial remission

    Time frame: 24 weeks

Secondary outcomes

  1. Proportion of Subjects With Complete Remission or Partial Remission of Proteinuria

    Complete remission or partial remission of proteinuria

    Time frame: Weeks 8 and 12

  2. Proportion of Subjects With Complete Remission of Proteinuria

    Complete remission of proteinuria

    Time frame: Weeks 8, 12, and 24

  3. Proportion of Subjects With Reduction of Proteinuria

    Reduction of proteinuria

    Time frame: Weeks 8, 12, and 24

  4. Proportion of Subjects With Partial Remission of Proteinuria

    Partial remission of proteinuria

    Time frame: Weeks 8, 12, and 24

  5. Time to First Occurrence of Complete or Partial Remission of Proteinuria

    Complete OR partial remission of proteinuria

    Time frame: Up to 26 weeks

  6. Time to First Occurrence of Complete Remission of Proteinuria

    Complete remission of proteinuria

    Time frame: Up to 26 weeks

  7. Time to First Occurrence of Partial Remission of Proteinuria

    Partial remission of proteinuria

    Time frame: Up to 26 weeks

  8. Time to First Occurrence of 50% Reduction in Urine Protein Creatinine Ratio (UPCR) From Baseline

    50% reduction in Urine Protein Creatinine Ratio (UPCR) from baseline

    Time frame: Up to 26 weeks

  9. Duration of Reduced Urine Protein Creatinine Ratio (UPCR)

    Duration of reduced Urine Protein Creatinine Ratio (UPCR)

    Time frame: Up to 26 weeks

  10. Change From Baseline in Urine Protein Creatinine Ratio (UPCR)

    Change from baseline in Urine Protein Creatinine Ratio (UPCR)

    Time frame: Weeks 2,4,8,12,18,24

  11. Proportion of Subjects With a Confirmed Decrease From Baseline in Estimated Glomerular Filtration Rate (eGFR)

    Utilizing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula

    Time frame: Weeks 2,4,8,12,18,24

  12. Proportion of Subjects With a Confirmed Increase in Estimated Glomerular Filtration Rate (eGFR)

    Increase in Estimated Glomerular Filtration Rate (eGFR)

    Time frame: Week 24 to Week 26

  13. Change in Urine Protein Creatinine Ratio (UPCR)

    Change in Urine Protein Creatinine Ratio (UPCR)

    Time frame: Week 24 and Week 26

  14. Change in Estimated Glomerular Filtration Rate (eGFR)

    Change in estimated Glomerular Filtration Rate (eGFR)

    Time frame: Week 24 and Week 26

  15. Change From Baseline in Serum Creatinine, Serum Albumin and Estimate Glomerular Filtration Rate (eGFR)

    Change from baseline in serum creatinine, serum albumin and estimate Glomerular Filtration Rate (eGFR)

    Time frame: Weeks 2,4,8,12,18,24

  16. Quality of Life Assessments

    Mean change in Patient Reported Outcome Measurement Information System (PROMIS) measures

    Time frame: Week 24

  17. Quality of Life Assessments

    Change from baseline in Kidney Disease Quality of Life-Short Form (KDQOL-SF)

    Time frame: Week 24

  18. Safety and Tolerability (Treatment-Emergent Adverse Events)

    Incidence and number of treatment-emergent adverse events

    Time frame: 24 weeks

  19. Renal Biopsy

    Descriptive analyses of changes in histopathology will be evaluated in post treatment renal biopsies in a subset of patients

    Time frame: 24 weeks

07

Results

Posted Sep 16, 2021
Limitations and caveats
Due to difficulties enrolling appropriate Focal Segmental Glomerulosclerosis (FSGS) patients, Aurinia terminated the clinical trial early. Focal Segmental Glomerulosclerosis (FSGS) is a rare disease with an estimated 40,000 adult patients in the USA. Only five subjects were enrolled into the clinical trial.

Participant flow

Participant flow — Overall Study
MilestoneVoclosporin Cohort 1Voclosporin Cohort 2
Started50
Week 1: 7.9 mg twice daily50
Week 2: 15.9 mg twice daily50
Weeks 3 - 24: 23.7 mg twice daily50
Completed40
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryProportion of Subjects With Remission of Proteinuria

Complete remission OR Partial remission

Time frame:
24 weeks

No measurements were reported for this outcome.

SecondaryProportion of Subjects With Complete Remission or Partial Remission of Proteinuria

Complete remission or partial remission of proteinuria

Time frame:
Weeks 8 and 12

No measurements were reported for this outcome.

SecondaryProportion of Subjects With Complete Remission of Proteinuria

Complete remission of proteinuria

Time frame:
Weeks 8, 12, and 24

No measurements were reported for this outcome.

SecondaryProportion of Subjects With Reduction of Proteinuria

Reduction of proteinuria

Time frame:
Weeks 8, 12, and 24

No measurements were reported for this outcome.

SecondaryProportion of Subjects With Partial Remission of Proteinuria

Partial remission of proteinuria

Time frame:
Weeks 8, 12, and 24

No measurements were reported for this outcome.

SecondaryTime to First Occurrence of Complete or Partial Remission of Proteinuria

Complete OR partial remission of proteinuria

Time frame:
Up to 26 weeks

No measurements were reported for this outcome.

SecondaryTime to First Occurrence of Complete Remission of Proteinuria

Complete remission of proteinuria

Time frame:
Up to 26 weeks

No measurements were reported for this outcome.

SecondaryTime to First Occurrence of Partial Remission of Proteinuria

Partial remission of proteinuria

Time frame:
Up to 26 weeks

No measurements were reported for this outcome.

SecondaryTime to First Occurrence of 50% Reduction in Urine Protein Creatinine Ratio (UPCR) From Baseline

50% reduction in Urine Protein Creatinine Ratio (UPCR) from baseline

Time frame:
Up to 26 weeks

No measurements were reported for this outcome.

SecondaryDuration of Reduced Urine Protein Creatinine Ratio (UPCR)

Duration of reduced Urine Protein Creatinine Ratio (UPCR)

Time frame:
Up to 26 weeks

No measurements were reported for this outcome.

SecondaryChange From Baseline in Urine Protein Creatinine Ratio (UPCR)

Change from baseline in Urine Protein Creatinine Ratio (UPCR)

Time frame:
Weeks 2,4,8,12,18,24

No measurements were reported for this outcome.

SecondaryProportion of Subjects With a Confirmed Decrease From Baseline in Estimated Glomerular Filtration Rate (eGFR)

Utilizing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula

Time frame:
Weeks 2,4,8,12,18,24

No measurements were reported for this outcome.

SecondaryProportion of Subjects With a Confirmed Increase in Estimated Glomerular Filtration Rate (eGFR)

Increase in Estimated Glomerular Filtration Rate (eGFR)

Time frame:
Week 24 to Week 26

No measurements were reported for this outcome.

SecondaryChange in Urine Protein Creatinine Ratio (UPCR)

Change in Urine Protein Creatinine Ratio (UPCR)

Time frame:
Week 24 and Week 26

No measurements were reported for this outcome.

SecondaryChange in Estimated Glomerular Filtration Rate (eGFR)

Change in estimated Glomerular Filtration Rate (eGFR)

Time frame:
Week 24 and Week 26

No measurements were reported for this outcome.

SecondaryChange From Baseline in Serum Creatinine, Serum Albumin and Estimate Glomerular Filtration Rate (eGFR)

Change from baseline in serum creatinine, serum albumin and estimate Glomerular Filtration Rate (eGFR)

Time frame:
Weeks 2,4,8,12,18,24

No measurements were reported for this outcome.

SecondaryQuality of Life Assessments

Mean change in Patient Reported Outcome Measurement Information System (PROMIS) measures

Time frame:
Week 24

No measurements were reported for this outcome.

SecondaryQuality of Life Assessments

Change from baseline in Kidney Disease Quality of Life-Short Form (KDQOL-SF)

Time frame:
Week 24

No measurements were reported for this outcome.

SecondarySafety and Tolerability (Treatment-Emergent Adverse Events)

Incidence and number of treatment-emergent adverse events

Time frame:
24 weeks

No measurements were reported for this outcome.

SecondaryRenal Biopsy

Descriptive analyses of changes in histopathology will be evaluated in post treatment renal biopsies in a subset of patients

Time frame:
24 weeks

No measurements were reported for this outcome.

Adverse events

Collected over Day 1 to Week 26. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Voclosporin Cohort 1: Week 10/5 (0%)0/5 (0%)2/5 (40%)
Voclosporin Cohort 1: Week 20/5 (0%)0/5 (0%)0/5 (0%)
Voclosporin Cohort 1: Weeks 3-240/5 (0%)1/5 (20%)5/5 (100%)
Voclosporin Cohort 2———
Most frequent serious events
Most frequent serious events
EventVoclosporin Cohort 1: Week 1Voclosporin Cohort 1: Week 2Voclosporin Cohort 1: Weeks 3-24Voclosporin Cohort 2
DehydrationMetabolism and nutrition disorders0/50/51/5—
Acute Kidney InjuryRenal and urinary disorders0/50/51/5—
Most frequent other events
Showing 10 of 21
Most frequent other events
EventVoclosporin Cohort 1: Week 1Voclosporin Cohort 1: Week 2Voclosporin Cohort 1: Weeks 3-24Voclosporin Cohort 2
Glomerular filtration rate decreasedInvestigations0/50/53/5—
Blood creatine phosphokinase increasedInvestigations1/50/52/5—
HeadacheNervous system disorders0/50/52/5—
DizzinessNervous system disorders0/50/51/5—
ParaesthesiaNervous system disorders0/50/51/5—
TremorNervous system disorders0/50/51/5—
DiarrhoeaGastrointestinal disorders0/50/51/5—
Gingival bleedingGastrointestinal disorders0/50/51/5—
VomitingGastrointestinal disorders0/50/51/5—
PyrexiaGeneral disorders0/50/51/5—

Baseline characteristics

Trial ended prematurely before any patients were enrolled into Cohort 2

Age, Continuous
Age, Continuous(years)Voclosporin Cohort 1Voclosporin Cohort 2Total
Mean36.2 ± 20.71—36.2 ± 20.71
Sex: Female, Male
Sex: Female, Male(Participants)Voclosporin Cohort 1Voclosporin Cohort 2Total
Female2—2
Male3—3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Voclosporin Cohort 1Voclosporin Cohort 2Total
Hispanic or Latino2—2
Not Hispanic or Latino3—3
Unknown or Not Reported0—0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Voclosporin Cohort 1Voclosporin Cohort 2Total
American Indian or Alaska Native0—0
Asian0—0
Native Hawaiian or Other Pacific Islander0—0
Black or African American1—1
White3—3
More than one race0—0
Unknown or Not Reported1—1
Region of Enrollment
Region of Enrollment(participants)Voclosporin Cohort 1Voclosporin Cohort 2Total
United States3—3
Dominican Republic2—2
08

Study locations

23 sites
  • FSGS Investigative Center
    Denver, Colorado 80213, United States
  • FSGS Investigative Center
    Winter Park, Florida 32789, United States
  • FSGS Investigative Center
    Lawrenceville, Georgia 30046, United States
  • FSGS Investigative Center
    Chicago, Illinois 60611, United States
  • FSGS Investigative Center
    Iowa City, Iowa 52242, United States
  • FSGS Investigative Center
    Louisville, Kentucky 40202, United States
  • FSGS Investigative Center
    Shreveport, Louisiana 71101, United States
  • FSGS Investigative Center
    Detroit, Michigan 48201, United States
  • FSGS Investigative Center
    Minneapolis, Minnesota 55414, United States
  • FSGS Investigative Centre
    Saint Louis, Missouri 63110, United States
  • FSGS Investigative Center
    Newark, New Jersey 07103, United States
  • FSGS Investigative Center
    New York, New York 10032, United States
  • FSGS Investigative Center
    Chapel Hill, North Carolina 27599-7155, United States
  • FSGS Investigative Center
    Charlotte, North Carolina 28204, United States
  • FSGS Investigative Center
    Columbus, Ohio 43210, United States
  • FSGS Investigative Center
    Bethlehem, Pennsylvania 18017, United States
  • FSGS Investigative Center
    Dallas, Texas 75231, United States
  • FSGS Investigative Center
    Dallas, Texas 75246, United States
  • FSGS Investigative Center
    El Paso, Texas 79935, United States
  • FSGS Investigative Center
    Houston, Texas 77030, United States
  • FSGS Investigative Site
    Salt Lake City, Utah 84115, United States
  • FSGS Investigative Centre
    Santiago De Los Caballeros, 51000, Dominican Republic
  • FSGS Investigative Center
    Santo Domingo, Dominican Republic
09

References and documents

Publications

  • Ling SY, Huizinga RB, Mayo PR, Larouche R, Freitag DG, Aspeslet LJ, Foster RT. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin. Br J Clin Pharmacol. 2014 Jun;77(6):1039-50. doi: 10.1111/bcp.12309. PubMed 24330024 ↗
  • Ling SY, Huizinga RB, Mayo PR, Freitag DG, Aspeslet LJ, Foster RT. Pharmacokinetics of voclosporin in renal impairment and hepatic impairment. J Clin Pharmacol. 2013 Dec;53(12):1303-12. doi: 10.1002/jcph.166. Epub 2013 Oct 8. PubMed 23996158 ↗
  • Mayo PR, Huizinga RB, Ling SY, Freitag DG, Aspeslet LJ, Foster RT. Voclosporin food effect and single oral ascending dose pharmacokinetic and pharmacodynamic studies in healthy human subjects. J Clin Pharmacol. 2013 Aug;53(8):819-26. doi: 10.1002/jcph.114. Epub 2013 Jun 4. PubMed 23736966 ↗
  • Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, Ling S, Huizinga RB, Meier-Kriesche HU; PROMISE Investigators. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant. 2011 Dec;11(12):2675-84. doi: 10.1111/j.1600-6143.2011.03763.x. Epub 2011 Sep 22. PubMed 21943027 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in May 2020, 22 months.

Results were first posted in Sep 2021, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2018
First posted
Jul 26, 2018
StartActual
Jun 21, 2018
Primary completionActual
May 19, 2020
CompletionActual
May 19, 2020
Results first posted
Sep 16, 2021
Last update
Sep 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03598036
Lead sponsor
Aurinia Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Jul 26, 2018
Start date
Jun 21, 2018
Primary completion
May 19, 2020
Completion
May 19, 2020
Results posted
Sep 16, 2021
Last update
Sep 16, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voclosporin

Start the discussion